Vasa Denticity Quarterly Results for Trading Insights
In Sept 2025, Vasa Denticity (DENTALKART) reported revenue ₹74 Cr and net profit ₹5 Cr — revenue +23.3% YoY. Compare with DENTALKART fair price to assess whether the stock is under or overvalued.
DENTALKART Quarterly Results — Revenue, Profit & EPS Highlights
Vasa Denticity latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore DENTALKART price movement history to track price trends across different timeframes.
- Revenue of ₹74 Cr in Sept 2025 (+1.4% vs Mar 2025, +23.3% vs Sept 2024)
- Net Profit of ₹5 Cr in Sept 2025 (+25.0% vs Mar 2025, +0.0% vs Sept 2024)
- EBITDA of ₹7 Cr in Sept 2025 (+0.0% vs Mar 2025)
- Operating Margin of 8.0% in Sept 2025 (-1.0pp vs Mar 2025)
- Earnings Per Share of ₹2.83 in Sept 2025 (+11.4% vs Mar 2025)
Vasa Denticity Quarterly Results — Revenue, EBITDA, Net Profit & EPS
DENTALKART quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 74 | 73 | 62 | 73 | 60 | 1.4% | 23.3% |
| Net Profit (₹ Cr) | 5 | 4 | 3 | 1 | 5 | - | - |
| EBITDA (₹ Cr) | 7 | 7 | 4 | 3 | 7 | - | - |
| EPS (₹) | 2.83 | 2.54 | 1.65 | 0.79 | 3.35 | - | - |
| Operating Margin (%) | 8.0% | 9.0% | 5.0% | 2.0% | 11.0% | - | - |
DENTALKART Share Price Trend — 1-Year Movement Across Quarterly Results
Vasa Denticity 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit DENTALKART stock price BSE.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
DENTALKART vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Vasa Denticity latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹437,014.87 Cr | 1847.9 | 14,875 | 3,125 | +10.8% | - | 21.0% | 142.1 |
|
Divis Laboratories
Sept 2025 |
₹175,726.93 Cr | 6710.5 | 2,860 | 689 | +7.1% | - | 24.1% | 258.4 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹147,504.68 Cr | 4380.8 | 3,219 | 591 | +11.3% | - | 18.4% | 249.8 |
|
Lupin
Sept 2025 |
₹111,651.09 Cr | 2379.5 | 6,921 | 1,485 | +23.2% | - | 21.5% | 73.5 |
|
Cipla
Sept 2025 |
₹110,213.60 Cr | 1347.0 | 7,716 | 1,353 | +12.0% | - | 17.5% | 80.5 |
All amounts in ₹ Crores